Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14028449 | 0.86 | CHRNB2 (0.69) | CHRNB2CHRNA4MEN1KMT2AALDH1A1 | |
| SCHEMBL13214927 | 0.85 | CHRNB2 (0.58) | CHRNB2CHRNA4MEN1KMT2AALDH1A1 | |
| SCHEMBL27870159 | 0.84 | CHRNB2 (0.59) | CHRNB2CHRNA4MEN1KMT2AALDH1A1 | |
| SCHEMBL5149377 | 0.84 | CHRNB2 (0.62) | CHRNB2CHRNA4MEN1KMT2AALDH1A1 | |
| SCHEMBL31087898 | 0.84 | CHRNB2 (0.62) | CHRNB2CHRNA4MEN1KMT2AALDH1A1 | |
| SCHEMBL5518334 | 0.84 | CHRNB2 (0.62) | CHRNB2CHRNA4MEN1KMT2AALDH1A1 | |
| SCHEMBL30023557 | 0.84 | CHRNB2 (0.55) | CHRNB2CHRNA4MEN1KMT2AALDH1A1 | |
| SCHEMBL657597 | 0.84 | CHRNB2 (0.55) | CHRNB2CHRNA4MEN1KMT2AALDH1A1 | |
| SCHEMBL15498199 | 0.83 | CHRNB2 (0.73) | CHRNB2CHRNA4MEN1KMT2AALDH1A1 | |
| SCHEMBL28674578 | 0.83 | CHRNB2 (0.58) | CHRNB2CHRNA4MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897764-B2 | Thiourea derivatives | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2011-03-01 | — | — | US | disclosed |
| WO-2008154091-A1 | THIOUREA DERIVATIVES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306090-A1 | THIOUREA DERIVATIVES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306090-A1 | THIOUREA DERIVATIVES | EIF2AK2, IFNAR1, TPMT | CHRNB2 4538/4885CHRNA4 4301/4885MEN1 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.